Literature DB >> 26850227

Acylated and unacylated ghrelin during OGTT in Prader-Willi syndrome: support for normal response to food intake.

R J Kuppens1,2, P J D Delhanty3, T M Huisman3, A J van der Lely3, A C S Hokken-Koelega1,2.   

Abstract

BACKGROUND: Prader-Willi syndrome (PWS) is characterized by hyperphagia with impaired satiety. PWS patients have very high acylated ghrelin (AG) with normal unacylated ghrelin (UAG) levels, resulting in an elevated AG/UAG ratio, suggesting an intrinsic defect in the ghrelin regulation. Normally, food intake induces satiety and a drop in AG and UAG levels, but it is unknown if these levels also decline in PWS.
OBJECTIVE: To evaluate whether the high AG levels in PWS decline in response to glucose intake during an oral glucose tolerance test (OGTT), and to investigate the effects of growth hormone (GH) treatment on this response.
METHOD: Serum levels of AG, UAG and AG/UAG ratio during an OGTT were determined in 24 GH-treated patients with PWS (median age 19·0, range 14·2-25·9 years) and in 10 GH-stop patients (of whom five were in GH-treated group; 18·5, 14·5-20·3 years).
RESULTS: In GH-treated and GH-stop young adults with PWS, there was a sharp decline of AG levels and a decrease of UAG levels in the first 30 min after the glucose load, which resulted in a lower AG/UAG ratio. GH-treated patients had significantly lower AG levels than GH-stop patients at baseline and during the OGTT. All UAG levels and AG/UAG ratios were lower in the GH-treated patients, although not significantly.
CONCLUSIONS: In young adults with PWS, an oral glucose load significantly reduces AG and UAG levels, suggesting normal regulation of the ghrelin axis by food intake. GH treatment results in lower AG levels at baseline and during OGTT, suggesting a more favourable metabolic profile. Our findings might suggest that the impaired satiety is not the result of an abnormal response of the orexigenic ghrelin to food intake.
© 2016 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26850227     DOI: 10.1111/cen.13036

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  5 in total

Review 1.  Ghrelin forms in the modulation of energy balance and metabolism.

Authors:  Gianluca Gortan Cappellari; Rocco Barazzoni
Journal:  Eat Weight Disord       Date:  2018-10-24       Impact factor: 4.652

2.  Paradoxical leanness in the imprinting-centre deletion mouse model for Prader-Willi syndrome.

Authors:  David M Golding; Daniel J Rees; Jennifer R Davies; Dinko Relkovic; Hannah V Furby; Irina A Guschina; Anna L Hopkins; Jeffrey S Davies; James L Resnick; Anthony R Isles; Timothy Wells
Journal:  J Endocrinol       Date:  2016-10-31       Impact factor: 4.286

3.  Effects of a 12-Week Diet versus Diet plus Aerobic and Resistance Exercise Program on Acylated and Desacylated Ghrelin, and Ghrelin O-Acyltransferase in Adolescent Girls with Obesity.

Authors:  Hyun Jun Kim; Young Jin Tak; Sang Yeoup Lee; Jeong Pyo Seo
Journal:  Int J Environ Res Public Health       Date:  2022-01-28       Impact factor: 3.390

4.  High unacylated ghrelin levels support the concept of anorexia in infants with prader-willi syndrome.

Authors:  Veronique Beauloye; Gwenaelle Diene; Renske Kuppens; Francis Zech; Coralie Winandy; Catherine Molinas; Sandy Faye; Isabelle Kieffer; Dominique Beckers; Ricard Nergårdh; Berthold Hauffa; Christine Derycke; Patrick Delhanty; Anita Hokken-Koelega; Maithé Tauber
Journal:  Orphanet J Rare Dis       Date:  2016-05-04       Impact factor: 4.123

5.  Fasting and postprandial acyl and desacyl ghrelin and the acyl/desacyl ratio in obese patients before and after different types of bariatric surgery.

Authors:  Jolanta A Dardzińska; Łukasz Kaska; Monika Proczko-Stepaniak; Maria Szymańska-Gnacińska; Ewa Aleksandrowicz-Wrona; Sylwia Małgorzewicz
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2018-05-21       Impact factor: 1.195

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.